Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way - PubMed (original) (raw)
Review
Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way
Sanjiv Agarwala. Am J Clin Dermatol. 2003.
Abstract
Melanoma is a neoplasm with an incidence in the US that is rising at a rate second only to lung cancer in women. Early stage melanoma is curable, but advanced metastatic melanoma is almost uniformly fatal, even in 2003. The close relationship of melanoma with the immune system has led to a recent resurgence in the investigation of immunotherapy in the treatment of this disease. The two most widely investigated immunotherapy drugs for melanoma are interferon (IFN)-alpha and interleukin-2 (IL-2). The role of IFNalpha-2b in the adjuvant therapy of patients with localized melanoma at high risk for relapse has recently been established by the results of three large randomized trials conducted by the US Intergroup; all three trials demonstrated an improvement in relapse-free survival and two in overall survival. Recombinant IL-2 (rIL-2) has an overall response rate of 15-20% in metastatic melanoma and is capable of producing complete and durable remissions in about 6% of patients treated. Based upon these data, the US FDA has recently approved the use of high-dose bolus administration of rIL-2 for the therapy of patients with metastatic melanoma. Results of combination chemotherapy and immunotherapy regimens containing rIL-2 and IFNalpha (biochemotherapy) are promising, but conclusions regarding an advantage for this therapy in terms of survival must await the completion of ongoing randomized trials. The use of therapeutic vaccines is an ongoing area of research, and clinical trials of several types of vaccines (whole cell, carbohydrate, peptide) are being conducted in patients with intermediate and late-stage melanoma. In the setting of adjuvant therapy, to date, no vaccine has demonstrated a survival benefit in comparison with either observation or IFNalpha. Vaccines are also being tested in patients with metastatic melanoma to determine their immune effects and to define their activity in combination with other immunotherapeutic agents such as IL-2 or IFNalpha.
Similar articles
- Melanoma: immunotherapeutic approaches.
Agarwala SS, Kirkwood JM. Agarwala SS, et al. BioDrugs. 1999 Sep;12(3):193-208. doi: 10.2165/00063030-199912030-00003. BioDrugs. 1999. PMID: 18031176 - Combined chemoimmunotherapy in metastatic melanoma--is there a need for the double?
Schrader AJ. Schrader AJ. Anticancer Drugs. 2000 Mar;11(3):143-8. doi: 10.1097/00001813-200003000-00001. Anticancer Drugs. 2000. PMID: 10831272 Review. - The use of interferon-alpha in the treatment of cutaneous melanoma: a review.
Punt CJ. Punt CJ. Melanoma Res. 1998 Apr;8(2):95-104. doi: 10.1097/00008390-199804000-00001. Melanoma Res. 1998. PMID: 9610861 Review. - Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD, Jack A, Montenegro G, Degliuomini J, Wallack MK. Kalani AD, et al. G Ital Dermatol Venereol. 2008 Feb;143(1):59-70. G Ital Dermatol Venereol. 2008. PMID: 18833052 Review.
Cited by
- Interferon signaling and ferroptosis in tumor immunology and therapy.
Hu W, Zhao Z, Du J, Jiang J, Yang M, Tian M, Zhao P. Hu W, et al. NPJ Precis Oncol. 2024 Aug 10;8(1):177. doi: 10.1038/s41698-024-00668-w. NPJ Precis Oncol. 2024. PMID: 39127858 Free PMC article. - Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter.
Pisapia L, Pozzo GD, Barba P, Citro A, Harris PE, Maffei A. Pisapia L, et al. Results Immunol. 2012 Sep 27;2:174-83. doi: 10.1016/j.rinim.2012.09.001. eCollection 2012. Results Immunol. 2012. PMID: 24371581 Free PMC article. - Immunomodulatory cytokines as therapeutic agents for melanoma.
Nicholas C, Lesinski GB. Nicholas C, et al. Immunotherapy. 2011 May;3(5):673-90. doi: 10.2217/imt.11.45. Immunotherapy. 2011. PMID: 21554095 Free PMC article. Review. - Systematic review of medical treatment in melanoma: current status and future prospects.
Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Garbe C, et al. Oncologist. 2011;16(1):5-24. doi: 10.1634/theoncologist.2010-0190. Epub 2011 Jan 6. Oncologist. 2011. PMID: 21212434 Free PMC article. Review. - Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines.
Bill MA, Bakan C, Benson DM Jr, Fuchs J, Young G, Lesinski GB. Bill MA, et al. Mol Cancer Ther. 2009 Sep;8(9):2726-35. doi: 10.1158/1535-7163.MCT-09-0377. Epub 2009 Sep 1. Mol Cancer Ther. 2009. PMID: 19723881 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical